Here are four quick facts:
1. One analyst gave the shares a “buy” rating and three gave the shares a “neutral” rating on Feb. 29.
2. No analysts rated the shares a “sell” or “strong sell.”
3. On Jan. 28, Leerink Swann reiterated CONMED’s “outperform” rating.
4. Leerink Swann has a price target of $50 on CONMED shares.
More articles on devices:
InVivo Therapeutics receives Objective Performance Criterion for study: 5 insights
North America dominates global orthopedic prosthetic devices market: 5 things to know
Integra LifeSciences Holdings short interest decreases: 5 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.